Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 14

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

374

HTML

3267

Tables (1-1)

497

Sum=4138

Publishing Process of This Article

Item

Count

Browse

1397

Download

1314

Sum=2711

Apr 14, 2013 (publication date) through Nov 8, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Apr 14, 2013; 19(14): 2141-2143
Published online Apr 14, 2013. doi: 10.3748/wjg.v19.i14.2141

Table 1 Baseline characteristics and main treatment outcomes of our cohort (n = 15) n (%)

Baseline characteristics	Value
Characteristic
Male	1 (6.7)
Age, yr (range)	67 (62-76)
BCLC stage
B - intermediate	10 (66.7)
C - advanced	5 (33.3)
Child-Pugh score
5	6 (40)
6	9 (60)
Treatment outcomes
Overall survival, mo (range)	26.5 (10-36)
Liver decompensation	4 (26.7)
Hepatocellular carcinoma progression	3 (20.0)
Interruption of sorafenib therapy due to adverse events	0 (0)

All subjects achieved viral clearance following entecavir treatment before the initiation of sorafenib 800 mg/d.

Citation: D’Angelo S, Secondulfo M, De Cristofano R, Sorrentino P. Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma? World J Gastroenterol 2013; 19(14): 2141-2143
URL: https://www.wjgnet.com/1007-9327/full/v19/i14/2141.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i14.2141